Clinical Trial Update: Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations [Phase 2]

View source ↗

Summary

Phase 2 trial update on MAS825 for monogenic IL-18–driven autoinflammatory diseases, including NLRC4-GOF, XIAP deficiency, Autoinflammation With Infantile Enter…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoinflammation with Infantile Enterocolitis
• Cdc42-related Autoinflammatory Disease
• Nlrc4-related Autoinflammatory Disease
• Xiap Deficiency

Drugs mentioned

• MAS825

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations | Phase 2 | Status: ACTIVE_NOT_RECRUITING